HDAC6 inhibition decreases leukemic stem cell expansion driven by Hedgehog hyperactivation by restoring primary ciliogenesis. (September 2022)
- Record Type:
- Journal Article
- Title:
- HDAC6 inhibition decreases leukemic stem cell expansion driven by Hedgehog hyperactivation by restoring primary ciliogenesis. (September 2022)
- Main Title:
- HDAC6 inhibition decreases leukemic stem cell expansion driven by Hedgehog hyperactivation by restoring primary ciliogenesis
- Authors:
- Pezzotta, Alex
Gentile, Ilaria
Genovese, Donatella
Totaro, Maria Grazia
Battaglia, Cristina
Leung, Anskar Yu-Hung
Fumagalli, Monica
Parma, Matteo
Cazzaniga, Gianni
Fazio, Grazia
Alcalay, Myriam
Marozzi, Anna
Pistocchi, Anna - Abstract:
- Abstract: Aberrant activation of the Hh pathway promotes cell proliferation and multi-drug resistance (MDR) in several cancers, including Acute Myeloid Leukemia (AML). Notably, only one Hh inhibitor, glasdegib, has been approved for AML treatment, and most patients eventually relapse, highlighting the urgent need to discover new therapeutic targets. Hh signal is transduced through the membrane of the primary cilium, a structure expressed by non-proliferating mammalian cells, whose stabilization depends on the activity of HDAC6. Here we describe a positive correlation between Hh, HDAC6, and MDR genes in a cohort of adult AML patients, human leukemic cell lines, and a zebrafish model of Hh overexpression. The hyper-activation of Hh or HDAC6 in zebrafish drove the increased proliferation of hematopoietic stem and progenitor cells (HSPCs). Interestingly, this phenotype was rescued by inhibition of HDAC6 but not of Hh . Also, in human leukemic cell lines, a reduction in vitality was obtained through HDAC6, but not Hh inhibition. Our data showed the presence of a cross-talk between Hh and HDAC6 mediated by stabilization of the primary cilium, which we detect for the first time in zebrafish HSPCs. Inhibition of HDAC6 activity alone or in combination therapy with the chemotherapeutic agent cytarabine, efficiently rescued the hematopoietic phenotype. Our results open the possibility to introduce HDAC6 as therapeutic target to reduce proliferation of leukemic blasts in AML patients.Abstract: Aberrant activation of the Hh pathway promotes cell proliferation and multi-drug resistance (MDR) in several cancers, including Acute Myeloid Leukemia (AML). Notably, only one Hh inhibitor, glasdegib, has been approved for AML treatment, and most patients eventually relapse, highlighting the urgent need to discover new therapeutic targets. Hh signal is transduced through the membrane of the primary cilium, a structure expressed by non-proliferating mammalian cells, whose stabilization depends on the activity of HDAC6. Here we describe a positive correlation between Hh, HDAC6, and MDR genes in a cohort of adult AML patients, human leukemic cell lines, and a zebrafish model of Hh overexpression. The hyper-activation of Hh or HDAC6 in zebrafish drove the increased proliferation of hematopoietic stem and progenitor cells (HSPCs). Interestingly, this phenotype was rescued by inhibition of HDAC6 but not of Hh . Also, in human leukemic cell lines, a reduction in vitality was obtained through HDAC6, but not Hh inhibition. Our data showed the presence of a cross-talk between Hh and HDAC6 mediated by stabilization of the primary cilium, which we detect for the first time in zebrafish HSPCs. Inhibition of HDAC6 activity alone or in combination therapy with the chemotherapeutic agent cytarabine, efficiently rescued the hematopoietic phenotype. Our results open the possibility to introduce HDAC6 as therapeutic target to reduce proliferation of leukemic blasts in AML patients. Graphical Abstract: ga1 … (more)
- Is Part Of:
- Pharmacological research. Volume 183(2022)
- Journal:
- Pharmacological research
- Issue:
- Volume 183(2022)
- Issue Display:
- Volume 183, Issue 2022 (2022)
- Year:
- 2022
- Volume:
- 183
- Issue:
- 2022
- Issue Sort Value:
- 2022-0183-2022-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-09
- Subjects:
- Hh Hedgehog -- MDR Multi.drug resistance -- AML Acute Myeloid Leukemia -- HSPCs Hematopoietic stem and progenitor cells -- Ptch Patched -- Smo Smoothened -- Sufu Suppressor of fused -- PkA Protein kinase A -- Gli Glioma associated oncogenes -- PC Primary cilium -- HDAC Histone deacetylase -- NPM Nucleophosmin -- TubA TubastatinA -- cyclo Cyclopamine -- CHT Caudal hematopoietic tissue -- AraC Cytarabine
TubastatinA hydrochloride SML0044 (Sigma) -- cyclopamine hydrate C4116 (Sigma) -- Dymetil sulfoxide D8418 (Sigma) -- Roscovitine R7772 (Sigma) -- Glasdegib PZ0303 (Sigma) -- cytarabine PHR1787 (Sigma)
AML -- Zebrafish -- Hedgehog -- HDAC6 -- Primary cilium
Pharmacology -- Periodicals
Pharmacology -- Periodicals
Research -- Periodicals
Médicaments -- Recherche -- Périodiques
Pharmacologie -- Périodiques
615.105 - Journal URLs:
- http://www.sciencedirect.com/science/journal/10436618 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.phrs.2022.106378 ↗
- Languages:
- English
- ISSNs:
- 1043-6618
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6446.550000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 23307.xml